Abstract

Psoriasis is an incurable autoimmune disease characterized by patches of abnormal red, itchy and scaly skin. This work examined the modulation of inflammation, hyperproliferation and immune cell markers following topical application of fish oil (FO) in comparison to the antipsoriatic agents, betamethasone dipropionate (BD) and salicylic acid (SA), to GsdmA3Dfl/+ mice, a hair loss mutant which also exhibits epidermal hyperproliferation akin to psoriasis. The mice were dosed with 100 mg of the test formulation and after 10 days, the mice were sacrificed, skin sections excised and subjected to immunohistochemical determination of COX‐2, K17 and MAC‐1; and immunofluorescence of Ki‐67. Unchanged expression of the proinflammatory enzyme COX‐2 was observed in all treatments, suggesting the noninvolvement of COX‐2 in the aetiology of cutaneous aberration seen in GsdmA3Dfl/+ mice. Intense staining of K17 and MAC‐1 in the FO‐treated group mirrored the epidermal thickening seen observed in live mice by optical coherence tomography (OCT). The ratio of Ki‐67‐positive nuclei per 100 basal cells indicated that hyperproliferation of keratinocytes occurred in FO‐treated mice and the opposite was true for BD‐treated mice. There was a positive correlation (R 2 0.995) between Ki‐67 and the epidermal thickness data observed previously. In all immunochemical procedures, the combined BD, SA and FO formulation did not show any significant difference with the control group, reflecting observations seen previously. In conclusion, the epidermal changes observed following topical FO treatment on GsdmA3Dfl/+ mice involves an increase in cellular proliferation and macrophages, although COX‐2 does not appear to play an important role.

Highlights

  • Psoriasis is an incurable autoimmune disease characterized by patches of abnormal red, itchy and scaly skin

  • This confirmed that the increased epidermal thickness due to the presence of the fish oil (FO) was due to hyperproliferation of keratinocytes, rather than cellular enlargement or oedema resulting from the formulations

  • The relatively unchanged levels of Cyclooxygenase 2 (COX-2) expression in all treatment groups suggest a noninvolvement of COX-2 in the aetiology of the GsdmA3Dfl/+ phenotype

Read more

Summary

Introduction

Psoriasis is an incurable autoimmune disease characterized by patches of abnormal red, itchy and scaly skin. This work examined the modulation of inflammation, hyperproliferation and immune cell markers following topical application of fish oil (FO) in comparison to the antipsoriatic agents, betamethasone dipropionate (BD) and salicylic acid (SA), to GsdmA3Dfl/+ mice, a hair loss mutant which exhibits epidermal hyperproliferation akin to psoriasis. Intense staining of K17 and MAC-1 in the FO-treated group mirrored the epidermal thickening seen observed in live mice by optical coherence tomography (OCT). Psoriasis is an autoimmune disease characterized by patches of abnormal red, itchy and scaly skin. Abbreviations 13-HODE, 13-hydroxyoctadecanoic acid; ABC, avidin-biotin complex; BD, betamethasone dipropionate; COX-2, cyclooxygenase-2; DAPI, 40,6-diamidino-2-phenylindole; DHA, docosahexaenoic acid; DPX, distyrene, plasticizer, xylene; EPA, eicosapentanoic acid; FO, fish oil; H&E, haematoxylin and eosin stain; IFN-γ, interferon gamma; LA, linoleic acid; MAC-1, macrophage-1 antigen; OCT, optical coherence tomography; SA, salicylic acid.

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.